Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086340 · ClinicalTrials.gov registry record
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 779
- Enrollment target
NCT06086340 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 779 participants.
The verdict
NCT06086340 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 779 participants
- Enrollment target
Study Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States
Interventions
- DRUG Palbociclib
- DRUG Aromatase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 779 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2024-01-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06086340
The ClinicalTrials.gov registry entry for NCT06086340 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 779 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT06086340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06086340 about?
NCT06086340 is a clinical study titled "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.". A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed h...
What is the current status of trial NCT06086340?
This trial is currently completed. The enrollment target is 779 participants. The study started on 2023-09-29. Estimated completion is 2024-01-24.
What interventions are being tested in trial NCT06086340?
The interventions under investigation include: Palbociclib (DRUG), Aromatase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT06086340?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.